Claims for Patent: 9,271,968

Summary for Patent: 9,271,968

Title:	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Abstract:	Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin .delta. and rifaximin .epsilon. useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Inventor(s):	Viscomi; Giuseppe Claudio (Sasso Marconi, IT), Campana; Manuela (Bologna, IT), Confortini; Donatella (Calderara di Reno, IT), Barbanti; Maria (Bologna, IT), Braga; Dario (Bologna, IT)
Assignee:	ALFA WASSERMANN S.P.A. (IT)
Application Number:	14/262,612
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,271,968
Patent Claims:	1. A pharmaceutical composition comprising a therapeutically effective amount of rifaximin together with excipients, wherein the rifaximin has a X-ray powder diffraction pattern peaks at about 5.7.degree..+-.0.2, 6.7.degree..+-.0.2 and 8.0.degree..+-.0.2. 2. The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises a peak at about 7.1.degree..+-.0.2, 2.theta.. 3. The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at about 10.4.degree..+-.0.2, 2.theta.. 4. The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at about 11.3.degree..+-.0.2, 2.theta.. 5. The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at about 7.1.degree..+-.0.2 and 10.8.degree..+-.0.2, 2.theta.. 6. The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at about 12.1.+-.0.2, 2.theta.. 7. The pharmaceutical composition according to claim 1 wherein the X-ray powder diffractogram further comprises peaks at 7.1.degree..+-.0.2, 8.7.degree..+-.0.2, and 10.4.degree..+-.0.2, 2.theta.. 8. The pharmaceutical composition of claim 1, wherein the rifaximin has an X-ray powder diffraction pattern peaks at about 5.7.degree..+-.0.2, 6.7.degree..+-.0.2, 7.1.degree..+-.0.2, 8.0.degree..+-.0.2, 8.7.degree..+-.0.2, 10.4.degree..+-.0.2, 11.3.degree..+-.0.2, 12.1.degree..+-.0.2, 17.0.degree..+-.0.2, 17.3.degree..+-.0.2, 17.5.degree..+-.0.2, 18.5.degree..+-.0.2, 18.8.degree..+-.0.2, 19.1.degree..+-.0.2, 21.0.degree..+-.0.2 and 21.5.degree..+-.0.2, 2.theta.. 9. The pharmaceutical composition of claim 1, wherein the composition has a water content of between 2.5% and 6.0%. 10. The pharmaceutical composition according to claim 1 wherein the excipients are selected from the group consisting of diluting agents, binding agents, lubricating agents, disintegrating agents, coloring agents and flavoring agents. 11. The pharmaceutical composition according to claim 1, wherein the composition is in a solid form selected from granules, tablets capsules, and powders in sealed packets. 12. A pharmaceutical composition comprising a therapeutically effective amount of rifaximin together with excipients wherein the rifaximin has X-ray powder diffraction pattern peaks at about 7.3.degree..+-.0.2, 8.2.degree..+-.0.2 and 10.3.degree..+-.0.2, 2.theta.. 13. The pharmaceutical composition of claim 12, wherein the X-ray powder diffraction pattern further comprises peaks at 7.0.degree..+-.0.2 and 11.1 .degree..+-.0.2, 2.theta.. 14. The pharmaceutical composition of claim 12, wherein the X-ray powder diffraction pattern further comprises peaks at about 12.4.degree..+-.0.2, 8.7.degree..+-.0.2 and 11.7.degree..+-.0.2,2.theta.. 15. The pharmaceutical composition of claim 11, wherein the X-ray powder diffraction pattern further comprises peaks at about 17.5 .degree..+-.0.2 and 21.5.degree..+-.0.2, 2.theta.. 16. The pharmaceutical composition according to claim 11 wherein the X-ray powder diffraction pattern peaks comprises peaks at about 5.7.degree..+-.0.2, 6.7.degree..+-.0.2, 7.1.degree..+-.0.2, 8.0.degree..+-.0.2, 8.7.degree..+-.0.2, 10.4.degree..+-.0.2, 11.3.degree..+-.0.2, 12.1.degree..+-.0.2, 17.0.degree..+-.0.2, 17.3.degree..+-.0.2, 17.5.degree..+-.0.2, 18.5.degree..+-.0.2, 18.8.degree..+-.0.2, 19.1.degree..+-.0.2, 21.0.degree..+-.0.2 and 21.5.degree..+-.0.2, 2.theta.. 17. The pharmaceutical composition according to claim 12, wherein the excipients are selected from the group consisting of diluting agents, binding agents, lubricating agents, disintegrating agents, coloring agents and flavoring agents. 18. The pharmaceutical composition according to claim 12, wherein the composition is in a solid form, selected from granules, tablets capsules, and powders in sealed packets.